The Department of Veterans Affairs (VA) proposes to revise its medical benefits package regulation on the use of drugs, biologicals, and medical devices not approved by the Food and Drug Administration (FDA). The Right to Try Act of 2017 has changed how VA may utilize unapproved investigational drugs for eligible patients. This proposed rule aligns VA’s regulations with the Right to Try Act of 2017, FDA regulations concerning expanded access to drugs, biologicals, and medical devices not approved by the FDA, FDA’s regulations for investigational use of marketed drugs, biologics, and medical devices, and VA’s current practice to prescribe certain unapproved marketed drugs.